CACarla Abdelnour

Carla Abdelnour

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carla Abdelnour has a total of 205 co-authors. Here are the top co-authors by number of shared publications:

  • Kathleen L. Poston

    Department of Neurology and Neurological Sciences, Stanford University School of Medicine

    6 shared publications
  • Dag Aarsland

    Centre for Age‐Related Medicine Stavanger University Hospital Stavanger Norway

    4 shared publications
  • Daniel Ferreira

    Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Stockholm, Sweden

    4 shared publications
  • Lu Tian

    Department of Epidemiology and Population Health, Stanford University School of Medicine, CA

    4 shared publications
  • Alena M. Smith

    Department of Neurology and Neurological Sciences, Stanford University School of Medicine

    3 shared publications
  • Annegret Habich

    Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden

    3 shared publications

Latest Publications

  • Plasma P-Tau217 as a Prognostic, Monitoring, and Risk-Stratification Biomarker of Clinical Progression in Lewy Body Disease

    by Sara A. Lorkiewicz, Carla Abdelnour, MacKenzie L. Bolen, Alena M. Smith, Marian Shahid-Besanti, Dimuthu Hemachandra, Eva M. Müller-Oehring, Noah Siddiqui, Laia Montoliu-Gaya, Burak Arslan, et al.

  • Open Access

    Potential role of MRI to optimize clinical trial design for progressive supranuclear palsy and corticobasal degeneration

    by Jesús García-Castro, Lawren VandeVrede, Michael C. Donohue, Lídia Vaqué-Alcázar, Sara Rubio-Guerra, Judit Selma-González, Hilary W. Heuer, Alejandra O. Morcillo-Nieto, María Franquesa, Oriol Dols-Icardo, et al.

  • Open Access

    Plasma phosphorylated tau 217 detects amyloid-β in Neuronal Synuclein Disease

    by Alena M. Smith, Sara A. Lorkiewicz, Burak Arslan, Laia Montoliu-Gaya, Nicholas J. Ashton, Edward N. Wilson, Daniel Alcolea, Íñigo Rodríguez-Baz, Juan Fortea, Christina B. Young, et al.

    Background Multiple proteinopathies commonly coexist in neurodegenerative diseases, therefore it is critical to understand plasma biomarker performance to detect proteinopathies in these complex diseases. While plasma biomarkers can accurately detect amyloid-β in individuals with Alzheimer’s disease, their performance accuracy is unknown in individuals with Neuronal Synuclein Disease (NSD). Objective To determine the accuracy of plasma pTau217, pTau181, Aβ42/40, GFAP, and NfL to detect amyloid-β in NSD. Additionally, to establish and validate cut-points for the most promising amyloid-β plasma biomarker in NSD. Methods This cross-sectional cohort study analyzed data from two observational cohorts from Stanford University and Sant Pau Hospital. The discovery cohort participants were biologically-defined by NSD and Aβ status among clinical Lewy body disease (LBD), Alzheimer’s disease (AD), or cognitively unimpaired (CU) individuals. The two validation cohorts consisted of clinically-defined LBD participants. Data were analyzed from 2/2024-3/2025. Plasma pTau217, pTau181, Aβ42/40, GFAP, and NfL were analyzed as potential biomarkers for amyloid-β in NSD, using cerebrospinal fluid Aβ42/40 and Aβ positron emission tomography as reference gold-standards. Diagnostic accuracy was determined using Receiver Operating Characteristic (ROC) analysis. Results We included 253 participants (mean[SD] age=71[9.9] years), 180 from the discovery cohort and 73 from the clinical validation cohorts. In the discovery cohort, plasma pTau217, pTau181, Aβ42/40, and GFAP levels significantly differed between Aβ+ and Aβ-participants, regardless of NSD status. Plasma NfL levels were significantly higher in the NSD+/Aβ+ group compared to all other groups. Plasma pTau217 showed the largest median fold-change between Aβ+ and Aβ-participants and demonstrated the highest diagnostic performance in detecting amyloid-β in NSD (Area Under the Curve=0.92, 95% CI=0.81-0.98). Applying one-or two-reference cut points for plasma pTau217 in the validation cohorts could reduce the need for additional amyloid-β testing in 41-56% of clinically-defined LBD participants. Conclusions Plasma pTau217 accurately detects amyloid-β in NSD individuals, with reproducible cut points in clinical LBD cohorts. Our findings demonstrate plasma pTau217 is a cost-effective and minimally-invasive tool for determining amyloid-β in mixed-etiology neurodegenerative diseases of aging.

  • The Parkinson's Disease Composite of Executive Functioning

    by Christina B. Young, Brenna Cholerton, Alena M. Smith, Marian Shahid-Besanti, Carla Abdelnour, Elizabeth C. Mormino, Shu-Ching Hu, Kathryn A. Chung, Amie Peterson, Liana Rosenthal, et al.


  • Open Access

    How to advance the pharmacological management of cognitive impairment in Parkinson's disease

    by Carla Abdelnour, Lucy L Gibson, Lucia Batzu, Dag Aarsland

    Cognitive impairment is a common non-motor symptom in people with Parkinson's disease (PD) and is associated to poor clinical outcomes. Currently, rivastigmine is the only approved medication for PD dementia, and there are no treatments available for people with PD and mild cognitive impairment. To advance the pharmacological management of cognitive impairment in PD, it is essential to optimize clinical trial design. This includes refining cognitive outcome measures, ensuring longer study durations, and incorporating PD-specific cognitive assessments. Biomarkers offer valuable opportunities for screening, stratification, enrichment, and monitoring in trials, increasing the likelihood of detecting treatment effects. Additionally, adopting patient-centered approaches that prioritize inclusivity can enhance trial validity and address the current lack of diversity in PD studies. Digital cognitive assessments offer a promising tool for improving participation and enabling longitudinal monitoring, especially in underrepresented and mobility-challenged populations. By tackling these challenges, this review outlines strategies for advancing the pharmacological management of cognitive impairment in PD. It emphasizes the need for precise, inclusive, and biomarker-driven trials to accelerate drug development.


  • Open Access

    Patients with dementia with Lewy bodies display a signature alteration of their cognitive connectome

    by Roraima Yanez-Perez, Eloy Garcia-Cabello, Annegret Habich, Nira Cedres, Patricia Diaz-Galvan, Carla Abdelnour, Jon B. Toledo, José Barroso, Daniel Ferreira

    Cognition plays a central role in the diagnosis and characterization of dementia with Lewy bodies (DLB). However, the complex associations among cognitive deficits in different domains in DLB are largely unknown. To characterize these associations, we investigated and compared the cognitive connectome of DLB patients, healthy controls (HC), and Alzheimer’s disease patients (AD). We obtained data from the National Alzheimer’s Coordinating Center. We built cognitive connectomes for DLB (n = 104), HC (n = 3703), and AD (n = 1985) using correlations among 24 cognitive measures mapping multiple cognitive domains. Connectomes were compared using global and nodal graph measures of centrality, integration, and segregation. For global measures, DLB showed a higher global efficiency (integration) and lower transitivity (segregation) than HC and AD. For nodal measures, DLB showed higher global efficiency in most measures, higher participation (centrality) in free-recall memory, processing speed/attention, and executive measures, and lower local efficiency (segregation) than HC. Compared with AD, DLB showed lower nodal strength and local efficiency, especially in memory consolidation. The cognitive connectome of DLB shows a loss of segregation, leading to a loss of cognitive specialization. This study provides the data to advance the understanding of cognitive impairment and clinical phenotype in DLB, with implications for differential diagnosis.


  • Open Access

    The Alzheimer’s Association Revised Criteria for Diagnosis and Staging of Alzheimer’s Disease – Where does Lewy body dementia stand?

    by Carla Abdelnour

    Dementia patients often received one clinical diagnosis, yet most of these cases present multiple underlying pathologies. Bringing the transition from clinical‐based to biological‐based diagnosis holds promise with the diagnostic criteria proposed by the Alzheimer’s Association (AA) Revised Criteria for Diagnosis and Staging of Alzheimer’s Disease and the Neuronal Synuclein Disease Integrated Staging System (NSD‐ISS). This session aims to explore the practical implications of the AA revised criteria for diagnosing and designing clinical trials in Lewy body disease (LBD).The updated version of the AA criteria proposes 3 biomarker categories: core Alzheimer’s disease (AD) biomarkers, non‐specific biomarkers, and biomarkers for common non‐AD co‐pathologies, including synucleinopathy (asyn). Utilizing the seeding amplification assay (SAA) to detect asyn pathology expands the biomarker toolkit, historically dominated by AD biomarkers. Identifying asyn in vivo in dementia cases enables recognizing underlying LBD, potentially reducing oversight of LBD cases with concurrent AD, which are less likely to present core features (particularly females).The AA criteria emphasize the role of clinical judgment in cases with comorbid pathology, proposing a biomarker profile for characterization. Challenges in evaluating several biomarkers in the clinical setting may be addressed using biofluid biomarkers and a stepwise process guided by clinical judgment.Practical applications of these criteria include their role as inclusion/exclusion criteria and stratification of LBD clinical trials. Similarly, in AD clinical trials, this framework allows excluding patients with comorbid pathologies to achieve a homogeneous study population.The AA revised criteria, along with the NSD‐ISS, serve as starting points for hypothesis testing. Future directions involve updating these frameworks with a patient‐centered approach, engaging patients and caregivers to understand the implications of biological‐based diagnosis. Longitudinal studies analyzing multiple comorbid pathologic changes are essential for determining the timeline of each pathology’s development. Finally, it is envisioned the creation of a comprehensive system to stratify disease progression of neurodegenerative diseases by incorporating biomarkers, demographic, clinical, and genetic data.


  • Open Access

    The Parkinson's Disease Composite of Executive Functioning

    by Christina B. Young, Brenna Cholerton, Alena M. Smith, Marian Shahid-Besanti, Carla Abdelnour, Elizabeth C. Mormino, Shu-Ching Hu, Kathryn A. Chung, Amie Peterson, Liana Rosenthal, et al.

    Executive functioning is one of the first domains to be impaired in Parkinson disease (PD), and the majority of patients with PD eventually develop dementia. Thus, developing a cognitive endpoint measure specifically assessing executive functioning is critical for PD clinical trials. The objective of this study was to develop a cognitive composite measure that is sensitive to decline in executive functioning for use in PD clinical trials. We used cross-sectional and longitudinal follow-up data from PD participants enrolled in the PD Cognitive Genetics Consortium, a multicenter setting focused on PD. All PD participants with Trail Making Test, Digit Symbol, Letter-Number Sequencing, Semantic Fluency, and Phonemic Fluency neuropsychological data collected from March 2010 to February 2020 were included. Baseline executive functioning data were used to create the Parkinson's Disease Composite of Executive Functioning (PaCEF) through confirmatory factor analysis. We examined the changes in the PaCEF over time, how well baseline PaCEF predicts time to cognitive progression, and the required sample size estimates for PD clinical trials. PaCEF results were compared with the Montreal Cognitive Assessment (MoCA), individual tests forming the PaCEF, and tests of visuospatial, language, and memory functioning. A total of 841 participants (251 no cognitive impairment [NCI], 480 mild cognitive impairment [MCI], and 110 dementia) with baseline data were included, of which the mean (SD) age was 67.1 (8.9) years and 270 were women (32%). Five hundred forty five PD participants had longitudinal neuropsychological data spanning 9 years (mean [SD] 4.5 [2.2] years) and were included in analyses examining cognitive decline. A 1-factor model of executive functioning with excellent fit (comparative fit index = 0.993, Tucker-Lewis index = 0.989, and root mean square error of approximation = 0.044) was used to calculate the PaCEF. The average annual change in PaCEF ranged from 0.246 points per year for PD-NCI participants who remained cognitively unimpaired to -0.821 points per year for PD-MCI participants who progressed to dementia. For PD-MCI, baseline PaCEF, but not baseline MoCA, significantly predicted time to dementia. Sample size estimates were 69%-73% smaller for PD-NCI trials and 16%-19% smaller for PD-MCI trials when using the PaCEF rather than MoCA as the endpoint. The PaCEF is a sensitive measure of executive functioning decline in PD and will be especially beneficial for PD clinical trials.


  • Open Access

    Plasma pTau181 Reveals a Pathological Signature that Predicts Cognitive Outcomes in Lewy Body Disease

    by Carla Abdelnour, Christina B. Young, Marian Shahid‐Besanti, Alena Smith, Edward N. Wilson, Javier Ramos Benitez, Hillary Vossler, Melanie J. Plastini, Joseph R. Winer, Geoffrey A. Kerchner, et al.

    Objective: To determine whether plasma phosphorylated‐Tau181 (pTau181) could be used as a diagnostic biomarker of concurrent Alzheimer's disease neuropathologic change (ADNC) or amyloidosis alone, as well as a prognostic, monitoring, and susceptibility/risk biomarker for clinical outcomes in Lewy body disease (LBD).Methods: We studied 565 participants: 94 LBD with normal cognition, 83 LBD with abnormal cognition, 114 with Alzheimer's disease, and 274 cognitively normal. Plasma pTau181 levels were measured with the Lumipulse G platform. Diagnostic accuracy for concurrent ADNC and amyloidosis was assessed with Receiver Operating Characteristic curves in a subset of participants with CSF pTau181/Aβ42, and CSF Aβ42/Aβ40 or amyloid‐β PET, respectively. Linear mixed effects models were used to examine the associations between baseline and longitudinal plasma pTau181 levels and clinical outcomes.Results: Plasma pTau181 predicted concurrent ADNC and amyloidosis in LBD with abnormal cognition with 87% and 72% accuracy, respectively. In LBD patients with abnormal cognition, higher baseline plasma pTau181 was associated with worse baseline MoCA and CDR‐SB, as well as accelerated decline in CDR‐SB. Additionally, in this group, rapid increases in plasma pTau181 over 3 years predicted a faster decline in CDR‐SB and memory. In LBD patients with normal cognition, there was no association between baseline or longitudinal plasma pTau181 levels and clinical outcomes; however, elevated pTau181 at baseline increased the risk of conversion to cognitive impairment.Interpretation: Our findings suggest that plasma pTau181 is a promising biomarker for concurrent ADNC and amyloidosis in LBD. Furthermore, plasma pTau181 holds potential as a prognostic, monitoring, and susceptibility/risk biomarker, predicting disease progression in LBD. ANN NEUROL 2024;96:526–538


  • Open Access

    Differentiating Prodromal Dementia with Lewy Bodies from Prodromal Alzheimer’s Disease: A Pragmatic Review for Clinicians

    by Kathryn A. Wyman-Chick, Parichita Chaudhury, Ece Bayram, Carla Abdelnour, Elie Matar, Shannon Y. Chiu, Daniel Ferreira, Calum A. Hamilton, Paul C. Donaghy, Federico Rodriguez-Porcel, et al.

    This pragmatic review synthesises the current understanding of prodromal dementia with Lewy bodies (pDLB) and prodromal Alzheimer’s disease (pAD), including clinical presentations, neuropsychological profiles, neuropsychiatric symptoms, biomarkers, and indications for disease management. The core clinical features of dementia with Lewy bodies (DLB)—parkinsonism, complex visual hallucinations, cognitive fluctuations, and REM sleep behaviour disorder are common prodromal symptoms. Supportive clinical features of pDLB include severe neuroleptic sensitivity, as well as autonomic and neuropsychiatric symptoms. The neuropsychological profile in mild cognitive impairment attributable to Lewy body pathology (MCI-LB) tends to include impairment in visuospatial skills and executive functioning, distinguishing it from MCI due to AD, which typically presents with impairment in memory. pDLB may present with cognitive impairment, psychiatric symptoms, and/or recurrent episodes of delirium, indicating that it is not necessarily synonymous with MCI-LB. Imaging, fluid and other biomarkers may play a crucial role in differentiating pDLB from pAD. The current MCI-LB criteria recognise low dopamine transporter uptake using positron emission tomography or single photon emission computed tomography (SPECT), loss of REM atonia on polysomnography, and sympathetic cardiac denervation using meta-iodobenzylguanidine SPECT as indicative biomarkers with slowing of dominant frequency on EEG among others as supportive biomarkers. This review also highlights the emergence of fluid and skin-based biomarkers. There is little research evidence for the treatment of pDLB, but pharmacological and non-pharmacological treatments for DLB may be discussed with patients. Non-pharmacological interventions such as diet, exercise, and cognitive stimulation may provide benefit, while evaluation and management of contributing factors like medications and sleep disturbances are vital. There is a need to expand research across diverse patient populations to address existing disparities in clinical trial participation. In conclusion, an early and accurate diagnosis of pDLB or pAD presents an opportunity for tailored interventions, improved healthcare outcomes, and enhanced quality of life for patients and care partners.